Regulatory

Feb 11, 2016
There was scant praise from the medical community for the eighth and final budget plan from the Obama administration.
Feb 04, 2016
Valeant and Turing's fuzzy explanations of pricing practices to the House Oversight and Government Reform Committee cast a shadow over the broader industry, writes Jill Wechsler.
Feb 01, 2016
GOP critics of the Agency are planning more oversight of regulatory programs and policies. Jill Wechsler reports.
Jan 05, 2016
The last few months have been tough for pharmaceutical companies, and the political environment in Washington isn’t likely to improve in the coming year, writes Jill Wechsler.
Jan 04, 2016
OND Director John Jenkins would like to see sponsors invest in more “me-better” drugs—as opposed to “me-too” medicines—to expand treatment options for patients and to boost competition among manufacturers.
Dec 29, 2015
Jill Wechsler on why the FDA program that encourages biopharma companies to develop new treatments for rare and neglected diseases has been in the spotlight recently.
Dec 15, 2015
CDER director Janet Woodcock has laid out the Center's priority list for 2016. Jill Wechsler reports.
Dec 08, 2015
Pharmaceutical Executive
It's open season on pharmaceutical companies, as Congressional committees ramp up industry oversight and political candidates on all sides look to win points by attacking drug pricing and marketing.
Nov 30, 2015
The Parliamentary Assembly of the Council of Europe is the latest to clamber aboard the well-filled bandwagon now rumbling and rattling across Europe in an increasingly noisy debate over drug prices. Reflector reports.
Nov 20, 2015
There’s renewed optimism in the biomedical research community that years of effort finally may begin to pay off for developing cutting-edge gene and cellular treatments for debilitating and life-threatening conditions. Jill Wechsler reports.
native1_300x100
lorem ipsum